Moderna (MRNA) Stock Forecast & Price Target
MRNA Analyst Ratings
Hold
2Buy15Hold3Sell
Based on 20 analysts giving stock ratings to Moderna in the past 3 months
MRNA Stock 12 Month Forecast
Average Price Target
MXN 2,398.74▼(-41.78% Downside)Based on 20 Wall Street analysts offering 12 month price targets for Moderna in the last 3 months. The average price target is MXN 2,398.74 with a high forecast of MXN 4,320.79 and a low forecast of MXN 845.37. The average price target represents a -41.78% change from the last price of MXN 4,120.00.
Past 12 Months12 Month ForecastJan2026Oct2026
HighMXN 4.32K
AverageMXN 2.4K
LowMXN 845.37
Highest Price TargetHighestMXN 4,320.79Average Price TargetMXN 2,398.74Lowest Price TargetLowestMXN 845.37
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Geoff Meacham | Citi | MXN 1,502.88 | sell | -63.52%Downside | Reiterated | 10/27/26 | ||
| Alec Stranahan | Bank of America Securities | MXN 3,757.21→MXN 4,132.93 | hold | 0.31%Upside | Reiterated | 10/27/26 | ||
| Myles Minter | William Blair | ― | hold | ― | Downgraded | 10/27/26 | ||
| Luca Issi | RBC Capital | MXN 2,442.19 | hold | -40.72%Downside | Reiterated | 10/27/26 | ||
| Edward Tenthoff | Piper Sandler | MXN 3,137.27→MXN 4,320.79 | buy | 4.87%Upside | Reiterated | 10/26/26 | ||
| Eliana Merle | Barclays | MXN 2,348.26 | hold | -43.00%Downside | Reiterated | 10/26/26 | ||
| Cory Kasimov | Evercore ISI | MXN 1,502.88 | hold | -63.52%Downside | Reiterated | 10/26/26 | ||
| Courtney Breen | Bernstein | MXN 845.37 | hold | -79.48%Downside | Reiterated | 10/25/26 | ||
| Salveen Richter | Goldman Sachs | MXN 2,573.69 | hold | -37.53%Downside | Reiterated | 10/25/26 | ||
| Tyler Van Buren | TD Cowen | MXN 751.44→MXN 1,690.74 | hold | -58.96%Downside | Reiterated | 10/21/26 | ||
| Terence Flynn | Morgan Stanley | MXN 1,784.67 | hold | -56.68%Downside | Assigned | 10/07/26 | ||
| Jessica Fye | J.P. Morgan | ― | sell | ― | Reiterated | 09/28/26 | ||
| Andrew Tsai | Jefferies | MXN 1,127.16→MXN 2,817.91 | hold | -31.60%Downside | Reiterated | 09/22/26 | ||
| Nico Chen | DBS | MXN 2,817.91 | hold | -31.60%Downside | Reiterated | 09/11/26 | ||
| Harry Gillis | Berenberg Bank | MXN 845.37→MXN 1,878.60 | hold | -54.40%Downside | Reiterated | 09/10/26 |
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Geoff Meacham | 10/27/26 | MXN 1,502.88 | sell | -63.52%Downside | Reiterated | Citi | ||
| Alec Stranahan | 10/27/26 | MXN 3,757.21→MXN 4,132.93 | hold | 0.31%Upside | Reiterated | Bank of America Securities | ||
| Myles Minter | 10/27/26 | ― | hold | ― | Downgraded | William Blair | ||
| Luca Issi | 10/27/26 | MXN 2,442.19 | hold | -40.72%Downside | Reiterated | RBC Capital | ||
| Edward Tenthoff | 10/26/26 | MXN 3,137.27→MXN 4,320.79 | buy | 4.87%Upside | Reiterated | Piper Sandler | ||
| Eliana Merle | 10/26/26 | MXN 2,348.26 | hold | -43.00%Downside | Reiterated | Barclays | ||
| Cory Kasimov | 10/26/26 | MXN 1,502.88 | hold | -63.52%Downside | Reiterated | Evercore ISI | ||
| Courtney Breen | 10/25/26 | MXN 845.37 | hold | -79.48%Downside | Reiterated | Bernstein | ||
| Salveen Richter | 10/25/26 | MXN 2,573.69 | hold | -37.53%Downside | Reiterated | Goldman Sachs | ||
| Tyler Van Buren | 10/21/26 | MXN 751.44→MXN 1,690.74 | hold | -58.96%Downside | Reiterated | TD Cowen | ||
| Terence Flynn | 10/07/26 | MXN 1,784.67 | hold | -56.68%Downside | Assigned | Morgan Stanley | ||
| Jessica Fye | 09/28/26 | ― | sell | ― | Reiterated | J.P. Morgan | ||
| Andrew Tsai | 09/22/26 | MXN 1,127.16→MXN 2,817.91 | hold | -31.60%Downside | Reiterated | Jefferies | ||
| Nico Chen | 09/11/26 | MXN 2,817.91 | hold | -31.60%Downside | Reiterated | DBS | ||
| Harry Gillis | 09/10/26 | MXN 845.37→MXN 1,878.60 | hold | -54.40%Downside | Reiterated | Berenberg Bank |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering Moderna
3 Months
Success Rate29/49 ratings generated profit
59%
Average Return
-10.15%
Copying Mani Foroohar's trades and holding each position for 3 Months would result in 59.18% of your transactions generating a profit, with an average return of -10.15% per trade.
1 Year
Success Rate32/49 ratings generated profit
65%
Average Return
-63.86%
Copying Mani Foroohar's trades and holding each position for 1 Year would result in 65.31% of your transactions generating a profit, with an average return of -63.86% per trade.
2 Years
Success Rate33/49 ratings generated profit
67%
Average Return
-125.39%
Copying Mani Foroohar's trades and holding each position for 2 Years would result in 67.35% of your transactions generating a profit, with an average return of -125.39% per trade.
MRNA Analyst Recommendation Trends
| Rating | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 |
| Buy | 3 | 5 | 4 | 5 | 1 |
| Hold | 43 | 44 | 31 | 38 | 23 |
| Sell | 11 | 9 | 5 | 4 | 2 |
| Strong Sell | 1 | 1 | 1 | 3 | 3 |
| total | 58 | 59 | 41 | 50 | 29 |
In the current month, MRNA has received 1 Buy Ratings, 23 Hold Ratings, and 5 Sell Ratings. MRNA average Analyst price target in the past 3 months is 2,398.74.
MRNA Financial Forecast
HighMXN -13.91
ConsensusMXN -20.60
LowMXN -29.69
MRNA Earnings Forecast
Next quarter’s earnings estimate for MRNA is -MXN 20.60 with a range of -MXN 29.69 to -MXN 13.91. The previous quarter’s EPS was -MXN 37.02. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
HighMXN 20.8B
ConsensusMXN 16.7B
LowMXN 15.7B
MRNA Sales Forecast
Next quarter’s sales forecast for MRNA is MXN 16.73B with a range of MXN 15.71B to MXN 20.82B. The previous quarter’s sales results were MXN 2.72B. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
MRNA Stock Forecast FAQ
What is MX:MRNA’s average 12-month price target, according to analysts?
Based on analyst ratings, Moderna’s 12-month average price target is Mex$2,398.74.
What is MX:MRNA’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for MX:MRNA, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Moderna a Buy, Sell or Hold?
Moderna has a consensus rating of Hold, which is based on 2 buy ratings, 15 hold ratings and 3 sell ratings.
What is Moderna’s share price target?
The average share price target for Moderna is Mex$2,398.74. This is based on 20 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is Mex$4,320.79, and the lowest forecast is Mex$845.37. The average share price target represents a 41.78% decrease from the current price of Mex$4,120.
What do analysts say about Moderna?
Moderna’s analyst rating consensus is a Hold. This is based on the ratings of 20 Wall Street analysts.
How can I buy shares of Moderna?
To buy shares of MX:MRNA, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
